Diabetic patients are considered to be at high risk for the development of atherosclerotic disease. Management
of hypercholesterolemia is of paramount importance to optimize cardiovascular outcomes in this subset
of patients and statins are regarded as the mainstay of treatment. However, the recent advent of PCSK-9 inhibitors
has provided a useful alternative in the management of dyslipidemia, especially when statins cannot be
tolerated or when hypolipidemic targets cannot be achieved. In this review, we discuss current trends in their
use, and we focus on their role in the management of diabetic dyslipidemia.
Keywords: PCSK9 inhibitors, dyslipidemia, diabetes, hypercholesterolemia, atherosclerotic disease, hypolipidemic.
Rights & PermissionsPrintExport